3 research outputs found
Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification
No full textDolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence
Two Cases of Viral Re-suppression After M184V+R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification
No full textDolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence
